Lorcaserin: A novel, selective 5-HT2C-receptor agonist for the treatment of obesity
Lorcaserin: A novel, selective 5-HT2C-receptor agonist for the treatment of obesity
复制标题
氯卡色林：一种用于治疗肥胖的新型选择性 5-HT2C 受体激动剂
作者：
PharmD Bcop Sam Abdelghany;PharmD Bcps Maribeth Pauli
肥胖症是一种流行病，在发达国家和发展中国家都已达到流行病的程度。在美国，估计有66%的成年人超重或肥胖。有几种可用的药物治疗肥胖症作为辅助饮食，运动和行为疗法。然而，使用这些药物的体重减轻是适度的，并且当药物停止时通常是可逆的，并且迫切需要新的，更有效的抗肥胖剂。
Obesity is a prevalent disease that has reached epidemic proportions in both the developed and developing world. In the United States, it is estimated that 66% of the adult population is overweight or obese. There are several available pharmacologic treatments for obesity used as an adjunct to diet, exercise, and behavioral therapy. However, weight loss with these agents is modest and usually reversible when the drug is discontinued, and novel, more-effective anti-obesity agents are desperately needed.